Head-to-head · WeighScore
Revel RX vs Zealthy
The verdict
Revel RX takes it — 77.3/100 to 46.7/100.
Revel RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Revel RX is a Michigan-based telehealth weight-loss platform offering compounded semaglutide at $89/month and compounded tirzepatide at $155/month — flat-rate at every dose tier.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Revel RX | Zealthy |
|---|---|---|
| WeighScore | 77.3/100 | 46.7/100 |
| Grade | C+ | C |
| Scorecard rank | #47 | #496 |
| Semaglutide | $89/mo (all doses, compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $155/mo (all doses, compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #47 · C+
Strengths
- Industry-low flat pricing: $89/mo for compounded semaglutide and $155/mo for tirzepatide at every dose
- LegitScript verified and BBB accredited with an A+ rating — above-average trust signals for a compounded platform
- Named pharmacy partners: Manifest Pharmacy and Red Rock Home Pharmacy (503A + 503B facilities)
- Free overnight cold shipping included; no hidden fees or dose-based price increases
- Clinical review by MD Integrations, an independent medical group, before any prescription is issued
Where it loses points
- States served are not publicly listed; eligible states requires completing intake to confirm coverage
- No labs, coaching, or ongoing health support disclosed in any public materials
- Compounded medications are not FDA-approved (site discloses this)
- Newer brand with limited public patient reviews or Trustpilot rating
- Pharmacy partners named but no accreditation details (PCAB, 503B cGMP) published on the site
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.